NeutralLOW severityEarnings7d ago

Ocular Therapeutix outlines Q4 2026 AXPAXLI NDA plan with $530.6M cash runway into 2028

Ocular Therapeutix outlines Q4 2026 AXPAXLI NDA plan with $530.6M cash runway into 2028 — $OCUL one-month chart
$OCUL daily closes over the past month · Wook of Wall Street artwork from market data

At a glance

WOOK’s read

$OCUL is near its 52-week low, trading at $7.01, just a tenth above its $6.00 bottom. Recent coverage has been neutral, with most attention arriving in the last week, and the Health Care sector shows calm today.

Written by Wook AI Nov 10, 7:54 AM ET from this page’s own figures at that time — not from the article — with every number checked against them. Not investment advice.

WOOKAI ASSISTANTREADY
WOOK AIASK ANYTHING · NEVER ADVISES

Ask about OCUL. Get explanations, comparisons and calculations with the source lookups shown.

Risk check · ocular therapeutixEvent risk Moderate
  • Key person: Filed with SEC
  • Clear: legal, regulatory, security, operational, financial integrity
From here · last month’s volatility 74% a year
Now $6.01Week $5.38–$6.64 (±10.4%)Month $4.73–$7.29 (±21.3%)
Early signals (1) — filed with the SEC or first reported, not yet widely covered
  • Key person · SEC 8-K, Item 5.02, Nov 9: Filed: a director or officer departed, was appointed, or had their pay changed. View filing →
Ask Wook AI

Close-to-close moves; beta-adjusted against the S&P 500, σ in the stock’s own daily noise; ranges one standard deviation. Reports are outlets’ words or SEC filings. Not a forecast or advice.

Wook analysis

What it means

Key points
  • What to watch: The headline zeroes in on $530 — a single figure, but it's the lens through which the bigger picture gets refracted.
  • How the stock is trading: $OCUL -3.22% in the latest session.
  • Timing: It was published while New York was trading, so the day's move may already include the first reaction.
Amount$530.6 million

Where the stock stands

Ocular Therapeutix ($OCUL) slid 3.22% to $6.01 in the latest session. Over the past month it is down 4.5%. It now sits 63% under the 52-week high of $16.44 and 1.2% above the year's low of $5.94, close to the bottom of its range. It has been a volatile year: the high was 2.8 times the low, so moves this size are not unusual for it.

What the filings say

In its latest report (10-Q, filed Nov 9, 2026), $OCUL lost $94.8M over the quarter to Sep 30, 2026 on revenue of $12.9M (-4.5% QoQ). Operations used $198.9M of cash over the nine months to Sep 30, 2026 — about $22.2M a month — against $530.6M in cash on Sep 30, 2026. At that pace the cash covers about 24 months. Total liabilities were $164.7M against $530.6M of cash on Sep 30, 2026. The company filed an 8-K — the form for material events — on Nov 9, the same day as this story; it is $OCUL's own account and the first thing to read. Figures are as filed with the SEC; the $OCUL page has the full statements.

How much coverage it is getting

Wook has no other story on Ocular Therapeutix from the last 30 days, so there is no recent run to compare this one with.

The bigger picture

Earnings reports are less about the numbers and more about how they stack up against what was expected — and how the future looks from there. Wook's supply-chain scanner shows no unusual stress in Health Care today.

What to watch next

The $OCUL page holds the full story — charts, filings, and models. Comparing coverage from different outlets is the fastest way to see if the story is being echoed or just echoed. Wook AI is here to help crunch the numbers, from past highs to this week’s chatter.

Discussion

No one has weighed in yet. Start the discussion on this story.

What happened after this published

Seeking Alpha published this on November 9, 2026. $OCUL has moved -10.43% ($6.71 to $6.01). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.

Headline and link are attributed to Seeking Alpha. Wook of Wall Street is an independent research tool and is not affiliated with Seeking Alpha. Nothing here is financial advice or a recommendation — research and educational content only.

Choose what Wook may measure. Essential sign-in and security cookies stay on.

Read the privacy policy